Type 2 Diabetes Mellitus Completed Phase 4 Trials for Exenatide (DB01276)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02455076Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 DiabetesTreatment
NCT00845182Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell FunctionTreatment
NCT01524705FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)Treatment
NCT02325960A Comparison of Exenatide and Insulin GlargineTreatment
NCT00667732How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 DiabeticsTreatment
NCT01744236SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesTreatment
NCT02288273Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.Treatment
NCT02533453A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.Treatment
NCT02467920Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DMTreatment
NCT02449603Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 DiabetesTreatment
NCT02092597Safety Evaluation of Adverse Reactions in DiabetesTreatment
NCT00353834The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 DiabetesTreatment
NCT00477581A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes MellitusTreatment
NCT00729326Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a ThiazolidinedioneTreatment
NCT00766857Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart FailureTreatment
NCT00870194A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus MetforminTreatment
NCT00948168Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 DiabetesTreatment
NCT00974272Effects of Exenatide on Postprandial Hyperlipidemia and InflammationTreatment
NCT01006889Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver DiseaseTreatment
NCT01181986The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and PrediabetesBasic Science
NCT01381926Changes in Bone Turnover With Exposure to a GLP-1 Receptor AgonistHealth Services Research
NCT01432405Effect Of Exenatide Treatment on Liver Fat Content in Patients With DiabetesTreatment
NCT01951651Effect of Exenatide on Liver and Heart Fat and InflammationTreatment
NCT02380521Exenatide Once Weekly, Cardiovascular Risk and Type-2 DiabetesTreatment
NCT02303730Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 DiabetesTreatment
NCT01776788Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic PatientsTreatment
NCT01076842Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes TreatmentTreatment